What sector does Regeneron Pharmaceuticals belong to?

Regeneron Pharmaceuticals operates in the Health Care sector, specifically the Biotechnology industry, and is listed on the US markets.

What is the current share price of REGN?

As of the latest available quote, REGN traded at $781.49. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of REGN?

Regeneron Pharmaceuticals has a price-to-earnings (P/E) ratio of about 19.34. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of REGN?

The market capitalisation of Regeneron Pharmaceuticals is approximately $84.87B.

Is Regeneron Pharmaceuticals profitable?

For its latest reported financial year, Regeneron Pharmaceuticals recorded a net profit margin of about 31.41%.

Does REGN pay a dividend?

Regeneron Pharmaceuticals currently has a dividend yield of about 0.46%.

What is the return on equity (ROE) of REGN?

Regeneron Pharmaceuticals has a return on equity (ROE) of about 14.21%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of REGN?

Over the past 52 weeks, REGN has traded between a low of $541.00 and a high of $859.34.

Regeneron Pharmaceuticals

REGN US Health Care Biotechnology

S&P 500 Nasdaq 100

$781.49

-1.48%

Delayed · cached 15 min

Fair value analysis

REGN

Regeneron Pharmaceuticals

$781.49

Close used for this calculation

$741.83Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

73/100

Profitability25/25

Returns8/25

Balance Sheet25/25

Efficiency15/25

Growth12/25

Strong

Quality radar

Consensus fair value

$741.83

Near FV

▼ -5.1% against the close used

Model range $526.00 – $1,122.03

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$526.00Fair value$741.83Bull$1,122.03

FairClose

52-week traded range

52W low $555.5152W high $852.03

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading close to the consensus fair value

Regeneron Pharmaceuticals closed at $781.49, 5.3% above the consensus fair value of $741.83 drawn from 8 valuation models.

Financial DNA score 73/100 — Strong. P/E of 18.8x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$745.77

-4.6%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

$528.63

-32.4%

√(22.5 × EPS × BVPS)

EPS=41.48, BVPS=299.42 · outside Graham range (P/E 18.8, P/B 2.6) — asset-light, treat as a rough floor

P/E Fair Value

$829.60

+6.2%

EPS × 20x (sector P/E)

EPS=41.48, Sector P/E=20x

Peter Lynch (PEG)

$1,122.03

+43.6%

EPS × Growth% (PEG = 1 is fair)

EPS=41.48, g=27.1%

EV/EBITDA

$683.11

-12.6%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=4.12B

Book Value (P/B)

$614.56

-21.4%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=299.42, ROE=14.2%, g=6%, r=10%

Reverse DCF

$781.49

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 6.3% | Historical: 27.1%

Margin of Safety

$526.00

-32.7%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=701.33, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer